Increasing IBD Cases Propel Mesalamine Market: Valued at $1.8 Billion in 2024, Forecast to Reach $3.4 Billion by 2035 at 6.8% CAGR
The Mesalamine Market is no longer just about treatment it’s about access, affordability, and global reach, led by a new wave of generic approvals. Industry Overview Mesalamine Mesalamine known as 5-aminosalicylic acid or 5-ASA is a medication used to treat Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. Mesalamine is a class of […]